Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC reduced its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 41.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,400,000 shares of the company's stock after selling 1,000,000 shares during the period. Teva Pharmaceutical Industries accounts for about 4.1% of Affinity Asset Advisors LLC's investment portfolio, making the stock its 5th largest holding. Affinity Asset Advisors LLC owned about 0.12% of Teva Pharmaceutical Industries worth $30,856,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of TEVA. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth $29,000. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $66,000. IFP Advisors Inc raised its stake in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC lifted its holdings in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 1.3 %

Shares of NYSE TEVA traded up $0.18 during mid-day trading on Friday, reaching $13.61. 8,836,138 shares of the company were exchanged, compared to its average volume of 9,902,722. The firm has a 50-day moving average of $15.45 and a 200 day moving average of $17.67. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a market cap of $15.43 billion, a price-to-earnings ratio of -9.38, a P/E/G ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TEVA. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday, April 14th. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Finally, Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.